A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease (NCT07094516)
A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension
🩺 Plain-English Summary (8th-Grade Level)
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Who can join: Review the eligibility criteria below.
Location: Banner Alzheimers Institute — Phoenix, Arizona
Age range: 50 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (74 Sites)
Showing the first 25 of 74 sites.
- Banner Alzheimers Institute — Phoenix, Arizona
- Irvine Center for Clinical Research — Irvine, California
- University of California San Diego — La Jolla, California
- University of California at Los Angeles — Los Angeles, California
- Jem Research Institute — Atlantis, Florida
- Visionary Investigators Network — Aventura, Florida
- K2 Medical Research LLC — Maitland, Florida
- K2 Medical Research LLC — Maitland, Florida
- Renstar Medical Research — Ocala, Florida
- Charter Research The Villages — The Villages, Florida
- Alzheimers Research Treatment Ctr — Wellington, Florida
- Alzheimers Research Treatment Ctr — Wellington, Florida
- Conquest Research — Winter Park, Florida
- Hawaii Pacific Neuroscience LLC — Honolulu, Hawaii
- University of Kansas Hospital — Fairway, Kansas
- ActivMed Practices and Research — Methuen, Massachusetts
- Citizens Memorial Hospital Neurology CLinic — Bolivar, Missouri
- Lou Ruvo Center for Brain Health — Las Vegas, Nevada
- UNC Hosp Invest Drug Serv Pharm — Chapel Hill, North Carolina
- The Ohio State University — Columbus, Ohio
- Neural Net Research — Portland, Oregon
- Abington Neurological Associates Ltd — Willow Grove, Pennsylvania
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
- University of Washington Medical Center — Seattle, Washington
- Novartis Investigative Site — Camperdown, New South Wales
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.